MedTrace Logo

Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer

NCT05247268 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2025-04-06

No results posted yet for this study

Summary

To see if Gonadotropin-releasing hormone analogue (GnRHa) combined with aromatase inhibitors (AIs) will achieve better complete response rate than megestrol acetate or medroxyprogesterone acetate (MA/MPA) alone as fertility-sparing treatment for patients with early endometrial carcinoma.

Conditions

  • Endometrial Neoplasm Malignant Stage I

Interventions

DRUG

Megestrol Acetate 160 MG Oral Tablet

At a dosage of 160 mg/day

DRUG

Medroxyprogesterone Acetate 500 MG

At a dosage of 500 mg/day

DRUG

Triprorelin Acetate

Intramuscular injection of 3.75mg was given 4 weeks apart and the maximum use are 6 courses

DRUG

Letrozole 2.5mg

At a dosage of 2.5mg/day and no more than 24 weeks

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    collaborator OTHER

  • Fudan University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-11
Primary Completion
2027-03-10
Completion
2027-09-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05247268 on ClinicalTrials.gov